-
Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
27 Jun 2019 20:15 GMT
… of a Phase 1 trial of BCX9930, an … activity at low drug concentrations in several … BioCryst Pharmaceuticals
BioCryst discovers novel, oral small-molecule medicines that … the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), …
-
BioCryst’s Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial
21 May 2019 11:00 GMT
… weeks of study drug treatment, 100 percent continued … trial, and plans to submit an NDA to the FDA … Pharmaceuticals
BioCryst discovers novel, oral small-molecule medicines … the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection …
-
BioCryst Completes Phase 1 Clinical Trial of Galidesivir
09 May 2019 20:15 GMT
… global Yellow Fever vaccine shortages. In … Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines … treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir … trials may not be commenced as expected; that the FDA …
-
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2019 Results - Earnings Call Transcript
08 May 2019 18:34 GMT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 … our ZENITH-1 trial of 7353 for the acute treatment of HAE … how we will approach the doctor [ph] analysis around the … forecasted demand for the underlying peramivir products. Importantly, these transactions …
-
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) price target raised to $18.00 by JMP Securities
02 Apr 2019 17:41 GMT
… Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that … of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which …
-
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2018 Results - Earnings Call Transcript
04 Mar 2019 18:18 GMT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 … randomized placebo-controlled trial of acute HAE treatment administered at-home … file a New Drug Application with the FDA by the end … development activity with Galidesivir and peramivir, we expect our 2019 …
-
BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks
23 Feb 2019 17:45 GMT
… drug if possible. Patient completed trial … treatment of acute angioedema attacks. About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals … discovers novel, oral small-molecule medicines … planned clinical trials or failure …
-
2018-2019 Influenza Vaccine Is Effective, Says CDC
21 Feb 2019 20:07 GMT
… , offer and encourage influenza vaccination for all unvaccinated patients ages … with antiviral medications.
The FDA has approved four antiviral drugs for treatment of … the 2018-2019 flu season: oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) …
-
Can you have the flu without a fever?
11 Feb 2019 14:23 GMT
… antiviral medications for the flu are oseltamivir (Tamiflu) and peramivir (Rapivab).
These treatments can … antiviral medications.
Additionally, people should see a doctor if they have the flu … cough
Children should visit a doctor if they show the following …
-
Flu widespread across most of US, with 3 new kids' deaths
25 Jan 2019 22:19 GMT
… samples testing positive for flu was up sharply, rising … to the antiviral drugs oseltamivir and peramivir, with two more … rise
Regarding hospitalizations for flu, the overall rate rose … Overall deaths from pneumonia and flu, an indicator that typically …
About
© 1995-2019